ArticleInfection and drug resistance2018
Extremely high levels of vancomycin can cause severe renal toxicity.
Article in Infection and drug resistance, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 28 citations in OpenAlex.
- Synthesis, anti-biofilm and molecular docking of amino-substituted chalcones targetingFuture medicinal chemistry · 2025Article
- A new evidence-based design-of-experiments approach for optimizing drug delivery systems with exemplification by emulsion-derived Vancomycin-loaded PLGA capsules.Scientific reports · 2024Article
- Article
- The emerging progress on wound dressings and their application in clinic wound management.Heliyon · 2023Review
- A rationally designed synthetic antimicrobial peptide against Pseudomonas-associated corneal keratitis: Structure-function correlation.Biophysical chemistry · 2022Article
- Highly Synergistic Effects of Melittin With Vancomycin and Rifampin Against Vancomycin and Rifampin ResistantFrontiers in microbiology · 2022Article
- Effect of First Trough Vancomycin Concentration on the Occurrence of AKI in Critically Ill Patients: A Retrospective Study of the MIMIC-IV Database.Frontiers in medicine · 2022Article
- Review
- The potential risk factors of nephrotoxicity during vancomycin therapy in Chinese adult patients.European journal of hospital pharmacy : science and practice · 2021Article
- Model-Informed Precision Dosing of Antibiotics in Pediatric Patients: A Narrative Review.Frontiers in pediatrics · 2021Review
- Vancomycin in ICU Patients with Gram-Positive Infections: Initial Trough Levels and Mortality.Therapeutics and clinical risk management · 2020Article
- Vancomycin trough level and loading dose.Infection and drug resistance · 2018Article
Corrections and comments
- Commented on by
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vancomycin has usually been associated with nephrotoxicity. Generally, this toxicity is presented as proximal tubular cells injury with or without necrosis and as acute interstitial nephritis. However, development of both lesions is uncommonly described in literature. We present a case of vancomycin-induced nephrotoxicity resulting in both acute interstitial nephritis and tubular cells damage confirmed by renal biopsy. Peak and trough levels of 77.11 and 63.60 μg/mL, respectively, were obtained at the first plasma determination. After 8 more plasma determinations and several hemodialysis sessions, vancomycin levels were undetectable 1 month after therapy was stopped. To our knowledge, this is the case report with the highest vancomycin trough levels developing both lesions and describing total vancomycin washout after a biopsy-proven vancomycin toxicity. In conclusion, early vancomycin therapeutic drug monitoring should be performed in order to avoid toxicities where, as seen in our patient, antibiotic exposure could last around 1 month after last dose administration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.